Sequential Revenue Growth (Q4 vs Q3)
13%
+13% QoQ
Strong sequential recovery in Q4, indicating underlying momentum.
SYNGENEINTERNATIONAL
Other
2026-04-??
Syngene International Ltd — Q4 FY26
Syngene reported Q4 FY26 revenue of ₹1,037 crore (+2% YoY, +13% QoQ) and EBITDA margin of 29%, beating revised guidance.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Syngene reported Q4 FY26 revenue of ₹1,037 crore (+2% YoY, +13% QoQ) and EBITDA margin of 29%, beating revised guidance. Full-year revenue grew 3% to ~₹4,190 crore, impacted by the Librella destocking headwind. PAT before exceptional items was ₹153 crore (-16% YoY). Management guided for a broadly flat FY27 with EBITDA margins in the mid-20s, as Librella revenue largely disappears in H1. The Bristol-Myers Squibb partnership extension to 2035 and investments in ADC, peptides, and biologics position the company for growth from FY28. Key risk: Librella revenue declines faster than new contracts ramp up, pressuring near-term revenue.
Key Numbers
Free Cash Flow (FY26)
₹521 crore
Healthy cash generation despite capex and Librella headwinds.
Net Cash Balance
₹1,800 crore
Strong balance sheet supports investments and buffers volatility.
CDMO Revenue Share (Q4)
41%
CDMO contributed 41% of Q4 revenue; CRO 59%.
Management Guidance
FY27 revenue broadly flat
Full-year revenue expected to be broadly flat vs FY26, with H2 meaningfully stronger than H1.
Management guidance revenueFY27 EBITDA margin in mid-20s
EBITDA margin guided to mid-20% range through disciplined cost management.
Management guidance marginsLibrella revenue minimal in H1 FY27
Librella revenue expected to be near zero in Q1 and Q2, with minor volumes in Q4.
Management guidance revenueBay View biologics facility operational in FY27
Preparations progressing; engineering batches expected in FY27 with regulatory approvals to follow.
Management guidance expansionKey Risks
Librella destocking impact
Librella revenue decline will continue to pressure revenue in H1 FY27, with near-zero contribution in Q1 and Q2.
high · management_commentaryBay View facility cost drag
Bay View costs are only partially capitalized; full impact on P&L not yet known, potentially pressuring margins.
medium · analyst_questionGeopolitical and tariff risks
Section 232 tariffs on pharma products could slow CDMO order flow, though management assesses negligible impact.
low · analyst_questionMargin trajectory uncertainty
Management cut margin guidance mid-year but beat it; path to high-20s margins remains unclear.
medium · data_observationNotable Quotes
FY27 will be a transition year for Syngene with important leadership changes already underway to position this company for its next phase of growth, particularly in CDMO, biologics, and emerging AI enabled service lines.
We expect a broadly flat performance for FY27 while maintaining EBITDA margins in the mid-20s through disciplined cost management and sharper operational executions.
The Labrella headwinds have clearly had material impacts last year 26 and as we've outlined will continue to have effects through 27 and those are now absorbed in the guidance framework.
Frequently Asked Questions
What was Syngene International's revenue in Q4 FY26?
Syngene International reported revenue of ₹1,036 Cr in Q4 FY26, representing a +2% change compared to the same quarter last year.
What guidance did Syngene International management give for FY27?
FY27 revenue broadly flat: Full-year revenue expected to be broadly flat vs FY26, with H2 meaningfully stronger than H1. FY27 EBITDA margin in mid-20s: EBITDA margin guided to mid-20% range through disciplined cost management. Librella revenue minimal in H1 FY27: Librella revenue expected to be near zero in Q1 and Q2, with minor volumes in Q4. Bay View biologics facility operational in FY27: Preparations progressing; engineering batches expected in FY27 with regulatory approvals to follow.
What are the key risks for Syngene International in FY27?
Key risks include Librella destocking impact — Librella revenue decline will continue to pressure revenue in H1 FY27, with near-zero contribution in Q1 and Q2.; Bay View facility cost drag — Bay View costs are only partially capitalized; full impact on P&L not yet known, potentially pressuring margins.; Geopolitical and tariff risks — Section 232 tariffs on pharma products could slow CDMO order flow, though management assesses negligible impact.; Margin trajectory uncertainty — Management cut margin guidance mid-year but beat it; path to high-20s margins remains unclear..
Did Syngene International meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Syngene International Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.